Tech Company Financing Transactions
Safi Biotherapeutics Funding Round
Safi Biotherapeutics closed a $4.7 million financing round on 11/3/2026. Investors included private investors.
Transaction Overview
Company Name
Announced On
11/3/2026
Transaction Type
Debt
Amount
$4,700,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to support the development of a readily transfusable, cryopreserved mRBC formulation.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
One Broadway, 14th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
As the cell therapy commercialization partner of a 5-year Department of Defense program to manufacture on-demand blood products, Safi Biotherapeutics and its collaborators are working to 'crack the code' of Cell Therapy 2.0 challenges of manufacturing at appropriate scale, high consistency of product, and economically viable cost of goods by integrating world-leading expertise in blood stem cell expansion, bioprocessing optimization, manufacturing scale-up and cryostorage.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Jon Mogford
Chief Executive Officer
Doug McConnell
Chief Operating Officer
Kyle Meetze
Co-Founder
Michael Mansour
Browse more venture capital transactions:
Prev: 11/3/2026: 42AI venture capital transaction
Next: 11/3/2026: Osstec venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs